Journal of Clinical Oncology, Vol 16, 470-479, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer

PC Clahsen, CJ van de Velde, C Duval, C Pallud, AM Mandard, A Delobelle- Deroide, L van den Broek, TM Sahmoud and MJ van de Vijver
European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium.

PURPOSE: Thirty percent of women with node-negative breast cancer will have a recurrence within 10 years after diagnosis. Molecular markers may identify those patients and predict whether they benefit from adjuvant therapy. The European Organization for Research and Treatment of Cancer (EORTC) conducted a randomized trial (EORTC 10854) to compare perioperative treatment with one course of fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus no further therapy. We studied tumors from premenopausal patients with node-negative breast cancer randomized in this trial to determine whether p53 accumulation, c-erbB-2 expression, percentage of Ki-67-positive cells, estrogen receptor (ER- immunoassay [IA]), progesterone receptor (PR-IA), and angiogenesis could be used as prognostic factors and predictors of responsiveness to adjuvant chemotherapy. PATIENTS AND METHODS: Paraffin-embedded tumor specimens from 441 premenopausal women with node-negative breast cancer were collected from the larger EORTC trial. Paraffin sections from the tumors were analyzed for immunohistochemical expression of p53, c-erbB- 2, Ki-67, ER, PR, and angiogenesis. RESULTS: Patients with p53-negative tumors showed a significant benefit from perioperative chemotherapy (P < .01), whereas patients who had p53-positive tumors did not (P = .80). At a median follow-up time of 49 months, univariate analyses for disease-free survival (DFS) failed to show prognostic value for p53, c- erbB-2 and angiogenesis. Both univariate and multivariate results showed Ki-67 positivity, ER-IA negativity, and a younger age to be associated with a worse prognosis. CONCLUSION: p53 accumulation was associated with a poor response to one perioperative course of FAC chemotherapy. Ki-67, ER-IA, and age are important prognostic factors in premenopausal women with node-negative breast cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. J. Chae, J. S. Bae, A. Lee, W. C. Park, Y. J. Seo, B. J. Song, J. S. Kim, and S. S. Jung p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 217 - 224. [Abstract] [Full Text] [PDF]

				S.-S. Ko, Y.-S. Na, C.-S. Yoon, J.-Y. Park, H.-S. Kim, M.-H. Hur, H.-K. Lee, Y.-K. Chun, S.-S. Kang, B.-W. Park, et al. The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node--Negative Breast Cancer: A Tissue Microarray Study International Journal of Surgical Pathology, April 1, 2007; 15(2): 98 - 109. [Abstract] [PDF]

				V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Ann. Onc., October 1, 2006; 17(10): 1504 - 1511. [Abstract] [Full Text] [PDF]

				K. I. Pritchard, L. E. Shepherd, F. P. O'Malley, I. L. Andrulis, D. Tu, V. H. Bramwell, M. N. Levine, and the National Cancer Institute of Canada Clinical T HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy N. Engl. J. Med., May 18, 2006; 354(20): 2103 - 2111. [Abstract] [Full Text] [PDF]

				P J Barrett-Lee Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S125 - S133. [Abstract] [Full Text] [PDF]

				J. Andersson, L. Larsson, S. Klaar, L. Holmberg, J. Nilsson, M. Inganas, G. Carlsson, J. Ohd, C.-M. Rudenstam, B. Gustavsson, et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF Ann. Onc., May 1, 2005; 16(5): 743 - 748. [Abstract] [Full Text] [PDF]

				H. Bonnefoi, S. Diebold-Berger, P. Therasse, A. Hamilton, M. van de Vijver, G. MacGrogan, L. Shepherd, N. Amaral, C. Duval, R. Drijkoningen, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann. Onc., March 1, 2003; 14(3): 406 - 413. [Abstract] [Full Text] [PDF]

				P. M. Ravdin Is Her2 of Value in Identifying Patients Who Particularly Benefit From Anthracyclines During Adjuvant Therapy? A Qualified Yes. J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 80 - 84. [Abstract] [Full Text] [PDF]

				D. F. Hayes, H. Yamauchi, G. Broadwater, C. T. Cirrincione, S. P. Rodrigue, D. A. Berry, J. Younger, L. L. Panasci, F. Millard, D. B. Duggan, et al. Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662 Clin. Cancer Res., September 1, 2001; 7(9): 2703 - 2711. [Abstract] [Full Text] [PDF]

				T. Petit, C. Borel, J.-P. Ghnassia, J.-F. Rodier, A. Escande, R. Mors, and P. Haegele Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant Setting Clin. Cancer Res., June 1, 2001; 7(6): 1577 - 1581. [Abstract] [Full Text] [PDF]

				H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				S. Geisler, P. E. Lønning, T. Aas, H. Johnsen, O. Fluge, D. F. Haugen, J. R. Lillehaug, L. A. Akslen, and A.-L. Børresen-Dale Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer Cancer Res., March 1, 2001; 61(6): 2505 - 2512. [Abstract] [Full Text]

				A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli, G. Gorzegno, B. DiMarco, S. Aguggini, G. Bolsi, F. Cirillo, et al. p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients Clin. Cancer Res., July 1, 2000; 6(7): 2751 - 2758. [Abstract] [Full Text]

				R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massutí, H. Cortés-Funes, and B. Lloveras Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2356 - 2362. [Abstract] [Full Text]

				E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer Cancer Res., April 1, 2000; 60(8): 2155 - 2162. [Abstract] [Full Text]

				P. H. M. Elkhuizen, H.-J. van Slooten, P. C. Clahsen, J. Hermans, C. J. H. van de Velde, L. C. J. M. van den Broek, and M. J. van de Vijver High Local Recurrence Risk After Breast-Conserving Therapy in Node-Negative Premenopausal Breast Cancer Patients Is Greatly Reduced by One Course of Perioperative Chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study J. Clin. Oncol., March 1, 2000; 18(5): 1075 - 1075. [Abstract] [Full Text] [PDF]

				T. A. H. Jarvinen, M. Tanner, V. Rantanen, M. Barlund, A. Borg, S. Grenman, and J. Isola Amplification and Deletion of Topoisomerase II{alpha} Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer Am. J. Pathol., March 1, 2000; 156(3): 839 - 847. [Abstract] [Full Text] [PDF]